Supplements vergleichen

Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.

Any time

Raloxifenhydrochlorid 60-mg-Tabletten (zugelassen für postmenopausale Osteoporose und Senkung des Brustkrebsrisikos)

Approved osteoporosis dosing is a single 5 mg intravenous infusion once yearly, given by a clinician (with adequate calcium/vitamin D and hydration). There is no validated longevity regimen; off-label geroprotective use would follow the same infusion under medical supervision.

Any time

Einmal jährliche intravenöse Infusion (5 mg)

• Active or past history of venous thromboembolism (deep-vein thrombosis, pulmonary embolism, retinal-vein thrombosis) — raloxifene raises clot risk
• Pregnancy and breastfeeding (can harm the fetus; contraindicated)
• Women of childbearing potential / premenopausal women (not indicated)

• Warfarin / anticoagulants
• Cholestyramine
• Systemic estrogens / other SERMs / aromatase inhibitors

• Hypocalcemia (uncorrected)
• Severe renal impairment (CrCl < 35)
• Pregnancy

• Nephrotoxic drugs (NSAIDs, aminoglycosides)
• Other calcium-lowering agents